Clearer skin made possible
In clinical studies after 3 MONTHS:
More people saw 75% SKIN IMPROVEMENT with CIBINQO vs an inactive pill
More people achieved CLEAR OR ALMOST CLEAR SKIN with CIBINQO vs an inactive pill
The recommended starting dose of CIBINQO is 100 mg once daily.
If the 100 mg dose isn't working well after 3 months, your doctor may increase your dose to 200 mg once daily. If the 200 mg dose isn't working well, your doctor may advise you to stop CIBINQO.
Less itch, quick results
After just 2 WEEKS over 5X more people felt less itch with CIBINQO 100 mg vs an inactive pill
Even after 3 MONTHS, more people felt itch relief taking CIBINQO vs an inactive pill
Proven relief in teens too
Studies of the safety and effectiveness of CIBINQO showed results in teens (ages 12-17) were consistent with those in adults
The most common side effects of CIBINQO include common cold, nausea, headache, herpes simplex including cold sores, increased blood level of creatine phosphokinase, dizziness, urinary tract infection, tiredness, acne, vomiting, mouth and throat pain, flu, stomach flu, bacterial skin infection, high blood pressure, allergic skin rash to something you contacted, stomach pain, shingles, and low platelet count. These are not all of the possible side effects of CIBINQO. For more information, talk to your doctor or learn more about the Most Important Information about CIBINQO.
CIBINQO was studied in clinical trials of people with moderate-to-severe eczema. Participants received either CIBINQO or an inactive pill (also known as a placebo). These participants and their doctors were not told which one they received. In two studies, people took either CIBINQO with topical steroids or an inactive pill with topical steroids. People were able to use a moisturizer in all of the studies.
Some of the trials lasted 3-4 months and focused on understanding the effectiveness and safety of CIBINQO. Improvement in area and severity of eczema-affected skin, skin clearance, and itch reduction were monitored.
Some of the people were able to enter another longer-term study that focused on safety.
Skin improvement, skin clearance, and itch reduction were monitored before, during, and at the end of the trials. The goal was to help answer the following question: Are patients who take CIBINQO more likely to have their eczema improve compared to patients who do not take CIBINQO?
Who participated in the studies?
Pfizer would like to thank everyone who participated in the CIBINQO clinical trials.
Seeing is believing
Take a look at before and after photos from our clinical trials to see results some people with moderate-to-severe eczema experienced.
Connect with a nearby doctor
Schedule an appointment with your doctor today. If you don’t have one yet, you can find one using this tool.
Ready to ask about CIBINQO?
To get the most out of your appointment,
use these tips and the doctor discussion
guide to help you prepare.